Dopamine toxicity involves mitochondrial complex I inhibition: implications to dopamine-related neuropsychiatric disorders

被引:110
作者
Ben-Shachar, D [1 ]
Zuk, R [1 ]
Gazawi, H [1 ]
Ljubuncic, P [1 ]
机构
[1] Technion ITT, Res Lab Psychobiol, Dept Psychiat, Bruce Rappaport Fac Med,Rambam Med Ctr, Haifa, Israel
关键词
dopamine; brain mitochondria; complex I; neurotoxicity; Parkinson's disease; schizophrenia;
D O I
10.1016/j.bcp.2004.02.015
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Dopamine, which is suggested as a prominent etiological factor in several neuropsychiatric disorders such as Parkinson's disease and schizophrenia, demonstrates neurotoxic properties. In such dopamine-related diseases mitochondrial dysfunction has been reported. Dopamine oxidized metabolites were shown to inhibit the mitochondrial respiratory system both in vivo and in vitro. In the present study, we suggest an additional mechanism for doparnine toxicity, which involves mitochondrial complex I inhibition by dopamine. In human neuroblastoma SH-SY5Y cells dopamine induced a reduction in ATP concentrations, which was negatively correlated to intracellular doparnine levels (r = -0.96, P = 0.012), and was already evident at non-toxic dopamine doses. In disrupted mitochondria doparnine inhibited complex I activity with IC50 = 11.87 +/- 1.45 muM or 8.12 +/- 0.75 muM in the presence of CoQ or ferricyanide, respectively, with no effect on complexes IV and Vactivities. The catechol moiety, but not the amine group, of dopamine is essential for complex I inhibition, as is indicated by comparing the inhibitory potential of functionally and structurally dopamine-related compounds. In line with the latter is the finding that chelatable FeCl2 prevented dopamine-induced inhibition of complex I. Monoamine oxidase A and B inhibitors, as well as the antioxidant butylated hydroxytoluene (BHT), did not prevent dopamine-induced inhibition, suggesting that dopamine oxidation was not involved in this process. The present study suggests that dopamine toxicity involves, or is initiated by, its interaction with the mitochondrial oxidative phosphorylation system. We further hypothesize that this interaction between doparnine and mitochondria is associated with mitochondrial dysfunction observed in dopamine-related neuropsychiatric disorders, such as schizophrenia and Parkinson's disease. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:1965 / 1974
页数:10
相关论文
共 81 条
  • [41] Metabolic enzyme expression in dopaminergic neurons in Parkinson's disease: An in situ hybridization study
    Kingsbury, AE
    Cooper, M
    Schapira, AHV
    Foster, OJF
    [J]. ANNALS OF NEUROLOGY, 2001, 50 (02) : 142 - 149
  • [42] PLATELET MITOCHONDRIAL-FUNCTION IN PARKINSONS-DISEASE
    KRIGE, D
    CARROLL, MT
    COOPER, JM
    MARSDEN, CD
    SCHAPIRA, AHV
    [J]. ANNALS OF NEUROLOGY, 1992, 32 (06) : 782 - 788
  • [43] LACLAU MJ, 1993, BIOCHIM BIOPHYS ACTA, V1141, P90
  • [44] CHRONIC PARKINSONISM IN HUMANS DUE TO A PRODUCT OF MEPERIDINE-ANALOG SYNTHESIS
    LANGSTON, JW
    BALLARD, P
    TETRUD, JW
    IRWIN, I
    [J]. SCIENCE, 1983, 219 (4587) : 979 - 980
  • [45] Combined effect of dopamine and MPP+ on membrane permeability in mitochondria and cell viability in PC12 cells
    Lee, CS
    Song, EH
    Park, SY
    Han, ES
    [J]. NEUROCHEMISTRY INTERNATIONAL, 2003, 43 (02) : 147 - 154
  • [46] EFFECTS OF ENHANCED STRIATAL DOPAMINE TURNOVER IN-VIVO ON GLUTATHIONE OXIDATION
    LOEFFLER, DA
    DEMAGGIO, AJ
    JUNEAU, PL
    HAVAICH, MK
    LEWITT, PA
    [J]. CLINICAL NEUROPHARMACOLOGY, 1994, 17 (04) : 370 - 379
  • [47] The Parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation - A novel mechanism of toxicity
    Lotharius, J
    O'Malley, KL
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (49) : 38581 - 38588
  • [48] LUSTY CJ, 1965, J BIOL CHEM, V240, P1804
  • [49] Masserano JM, 1996, MOL PHARMACOL, V50, P1309
  • [50] Inhibition of complex I by neuroleptics in normal human brain cortex parallels the extrapyramidal toxicity of neuroleptics
    Maurer, I
    Moller, HJ
    [J]. MOLECULAR AND CELLULAR BIOCHEMISTRY, 1997, 174 (1-2) : 255 - 259